|4Feb 13, 7:00 AM ET

Look Kirk 4

Research Summary

AI-generated summary

Updated

Oncolytics (ONCY) CFO Kirk Look Buys 12,000 Shares

What Happened
Kirk Look, Chief Financial Officer of Oncolytics Biotech Inc. (ONCY), acquired 12,000 shares on February 12, 2026. The transaction is reported as an open market or private purchase (code P) at $0.84 per share, with a reported total value of $10,104. This was a purchase rather than a sale.

Key Details

  • Transaction date: 2026-02-12 (report filed 2026-02-13) — filing appears timely.
  • Transaction type/code: Open market or private purchase (P).
  • Price and value: $0.84 per share; total reported consideration $10,104.
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Footnotes/plan: No 10b5-1 plan, tax withholding, or other special footnotes reported in the provided data.
  • Timeliness: Report filed the next day (not flagged as late in the supplied information).

Context
This was a direct share purchase, not an option exercise or award. The dollar amount is relatively small compared with many insider filings; purchases can be of interest to investors but filings do not disclose the insider’s motivation.